1 Abstract Purpose: We use reduced-order constrained optimization (ROCO) to create clinically acceptable IMRT plans quickly and automatically for advanced lung cancer patients. Our new ROCO implementation works with the treatment planning system and full dose calculation used at Memorial Sloan-Kettering Cancer Center, and we have implemented mean dose hard-constraints, along with the point-dose and dose-volume constraints that we used for our previous work on the prostate.
shifts the independent variables of the problem to the few dominant PCA modes. Sampling treatments is larger for these locally-advanced lung cases than for prostate cases, because the 71 larger treatment fields contain a greater total number of beamlets. For prostate cases there 72 are on the order of 10 3 beamlets, and for the lung cases that we consider, there are about 73 10 4 . Finally, IMRT for NSCLC often includes "rind" structures to prevent hot spots in non-74 specific normal tissues. Table I summarizes the major differences pertaining to treatment 75 planning between the prostate cases we had considered previously and the stage III NSCLC 76 cases considered in this paper.
77
The standard clinical approach to inverse IMRT planning is to combine all the evaluation 78 criteria specified by the physician into a scalar value using a weighted sum of several terms
79
(i.e., costlets 8 ). Each term includes a dose parameter (i.e., a minimum or maximum limit) 80 or a pair of dose-volume parameters (i.e., a point on a DVH curve), and reflects a clinical 81 objective. The weight of each term is the relative penalty imposed by the planner for not sat-82 isfying each objective. Such a formulation is easy to implement and can be optimized quickly 83 using gradient information, e.g., by Newton's methods 9 or conjugate gradient algorithms 10 . 
Criterion

122
In the following section, we briefly review each of these steps, placing emphasis on the new 123 features we have added; a more complete treatment is given in our previous paper 4 .
124
II. SUBJECTS AND METHODS
125
At 
A. Treatment plan criteria
135
The current MSKCC clinical evaluation protocol requires that the plan for IMRT treat-136 ment of primary lung tumors to 50-80 Gy for the PTV satisfies the conditions in Table II .
137
The mean dose constraint on the paired lungs usually ensures that the Lyman-Kutcher- or better, we deem coverage sufficient.
142
The dose to non-specific normal tissue surrounding the PTV is also of concern: "hot than ∼ 0.5 cm beyond the PTV, then the plan will be rejected by the treatment planner.
146
Excessive modulation of the intensity profiles, which can lead to delivery problems and 147 unnecessarily increased delivery time, is also not permitted in the clinic.
148
A difficulty in creating a treatment plan is that the definition of "clinically acceptable" can is not guaranteed to obey any particular constraint.
162
For the k th target, the corresponding objective function term is:
where N k is the number of points in the target, D i is the dose to the i th point in the target, are the penalties (weights) for under-and over-dosing.
166
The parameter set 
The sum in the second term is carried out over the lowest N intensity profile of a treatment plan to the N modes PCA modes with the greatest variance.
197
These modes U k span a reduced solution space.
198
During unconstrained optimization with conjugate-gradient methods, the MSKCC treat- 
executed rapidly
10 . Once optimization has completed, a long-range full dose calculation is 202 performed, and then the plan is evaluated based on this calculation.
203
We have found that, while this approach is sufficient for the sampling step, it is inaqequate 204 for the subsequent steps of ROCO. After the U k are determined, it is critical to make the 205 dose calculation for the PCA modes as accurate as possible, so that during the constrained 206 optimization, the solver has accurate information about OAR doses and target coverage. of the PCA modes. The goal of the optimization is specified as
for the voxels T in the target structures. This causes the optimizer to work toward uniform
222
PTV coverage. The doses to voxel i are given by
In this equation, the ξ k are the coefficients of the principal components, which are the 
229
For each organ, the point dose hard constraints are specified by
where i runs over the set of voxels in each organ or target. 
where N vox is the number of voxels in the structure. DVH constraints are implemented using 
240
There is also an additional constraint, which is that
where U jk is the value of beamlet j in mode k, and µ j is the value of beamlet j in the mean 242 of the samples. This ensures that the set of ξ k in the solution results in a non-negative 243 intensity distribution.
244
The dimensionality reduction by PCA makes it feasible to use a quadratic programming 
III. RESULTS
252
A. N samp and N modes 253
In order to help determine the optimal value for N samp , in Fig. 3 we studied how coverage 254 for the final ROCO plan varies with number of samples for all the patients in our study.
255
These results show that 50 samples are sufficient to achieve the desired 95% PTV coverage,
256
and that a larger number of samples is not likely to result in much improvement. Obtaining 257 the intensity profiles of the 50 samples requires 10-15 minutes of computer time.
258
We also studied the characterstics of the solutions from ROCO as we vary N modes in two 259 ways. First, we examined how much of the variance in the samples was recovered using the 260 PCA decomposition. The top panel of Fig. 4 shows the fraction of the variance recovered for 261 each patient as a function of the number of modes used, using an original set of 500 samples.
262
From this we determined that 25 modes was sufficient to recover 98% of the variance of for several patients using a surprisngly small number of modes. For example, patient 6 only 268 required 2 modes to obtain a plan that was close to acceptable.
269
Next, for each patient, we took the intensity vector for the clinical plans used by the 270 treatment planners I cl , and projected it into the reduced-dimension space, which allowed us 271 to measure the projection residual R:
The top panel of Fig. 5 shows how R behaves as a function of N modes . In this plot,
273
we see that there is initially a decrease in R as we increase the number of modes. Less In this section, we compare the ROCO plans to the plans that were used to treat these 12 280 patients in the clinic. In order to prepare for this comparison, the ROCO plans were eval- 
288
In all cases, ROCO achieved a plan satisfying the given input constraints, which is the 289 primary goal of using hard-constrained optimization. However, after the plan was normalized violated. This is not a failure of ROCO but rather a consequence of the difficulty of directly 294 comparing two plans, a difficult and well-known problem [26] [27] [28] [29] . As a result, it was sometimes 295 necessary to reoptimize patients using lower organ dose constraints or a lower PTV max 296 dose constraint. When ROCO is used as a standalone planning tool, without the intention 297 of comparing to a reference plan, this step is not necessary.
298
The plots in Fig. 6 show that for each case in our study, ROCO plans are competitive with 299 the treatment planner's plans. The required clinical constraints for the spinal cord maximum 300 dose and lung mean dose are satisfied in each case; the esophagus mean dose constraint was 301 satisfied when it was clinically possible to do so without sacrificing coverage. In Table III Significance was evaluated with the Wilcoxon signed-rank test; for ROCO, the median difference in doses to targets and organs was not significantly different from the treatment planner's.
not statistically significant.
310
These plans were generated in a short time, requiring around 30 minutes of CPU time.
311
In contrast, treatment planners using conventional IMRT optimization required around 3 312 hours for the same task, which is an important amount of time in a busy clinic. ROCO where fewer than 25 modes sufficed to bring the projection residual to less than 1%. constraints.
338
We set aside the rinds which had been previously created for each patient by the treatment 339 planners, and created a standardized rind structure for each patient by leaving a 4 mm 340 margin outside of the PTV, and then selecting a 3 cm annulus of tissue outside of this margin.
341
We then used ROCO to plan patients, first without the rind structures present, and then with 342 the standardized rinds in place during both the sampling and constrained optimization, and 343 finally leaving them out during the sampling and including them in constrained optimization we conclude that creation of a standard rind structure based only on the PTV geometry is 355 not a successful strategy for these kinds of lung cases. We observed that for these 3 cases,
356
the hot spot appeared near the intersection of two beam edges, which suggests a strategy 357 that might be used to generate rinds to deal with this problem.
IV. DISCUSSION AND CONCLUSIONS
In this paper, we extended our previous work on ROCO in several important ways. First,
360
we applied ROCO to a more complicated treatment site: the lung rather than the prostate,
361
and showed that the same general algorithmic strategy produced clinically acceptable plans.
362
We analyzed tradeoffs in sampling and dimensionality reduction and showed that acceptable 
